Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
Health sciences
Immunology
Virology
treatment
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
29
06
2022
revised:
10
10
2022
accepted:
30
01
2023
pubmed:
14
2
2023
medline:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.
Identifiants
pubmed: 36776936
doi: 10.1016/j.isci.2023.106124
pii: S2589-0042(23)00201-8
pmc: PMC9894676
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106124Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151758
Pays : United States
Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Curr Med Chem. 2021;28(26):5328-5338
pubmed: 33297909
Ann Rheum Dis. 2011 Aug;70(8):1507-10
pubmed: 21551509
Arthritis Rheum. 2010 Feb;62(2):542-52
pubmed: 20112381
Ann Rheum Dis. 2019 Apr;78(4):456-464
pubmed: 30679153
PLoS One. 2017 Sep 8;12(9):e0182927
pubmed: 28886017
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Arthritis Rheum. 2011 May;63(5):1255-64
pubmed: 21305508
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Microbiol. 2019 May 10;10:1057
pubmed: 31134045
J Immunol. 2020 Nov 1;205(9):2437-2446
pubmed: 32878912
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243
pubmed: 34028504
Lancet Neurol. 2020 May;19(5):391-401
pubmed: 32333897
Nat Commun. 2020 Aug 6;11(1):3924
pubmed: 32764665
J Clin Immunol. 2021 Feb;41(2):303-314
pubmed: 33188624
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Transplantation. 2020 Apr;104(4):856-863
pubmed: 31385933
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Arthritis Res Ther. 2014 Jan 02;16(1):R2
pubmed: 24383620
Immunity. 2022 Jun 14;55(6):1096-1104.e4
pubmed: 35483354
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Med (N Y). 2021 Jun 11;2(6):720-735.e4
pubmed: 33821250
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
Arthritis Res Ther. 2015 Mar 14;17:61
pubmed: 25888920
Blood. 2010 Jun 10;115(23):4699-706
pubmed: 20351305
Eur J Immunol. 1993 Apr;23(4):984-7
pubmed: 8458386
J Infect Dis. 2010 Dec 1;202(11):1659-66
pubmed: 20979459
Mol Cancer Ther. 2012 Aug;11(8):1623-6
pubmed: 22638145
Front Immunol. 2014 Feb 18;5:65
pubmed: 24600453
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Ann Rheum Dis. 2012 Dec;71(12):2006-10
pubmed: 22887851
Nat Commun. 2021 Aug 17;12(1):4984
pubmed: 34404803
EBioMedicine. 2020 Oct;60:102999
pubmed: 32950003
Nat Med. 2021 Feb;27(2):205-211
pubmed: 33469205
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
Front Immunol. 2020 Dec 03;11:611004
pubmed: 33343585